Common Equity: The sum of all common equity items.
Amylyx Pharmaceuticals, Inc. (AMLX) had Common Equity of $167.88M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-41.44M |
|
-- |
|
-- |
|
$42.86M |
|
$-42.86M |
|
$1.41M |
|
$-41.44M |
|
$-41.44M |
|
$-41.44M |
|
$-41.44M |
|
$-41.44M |
|
$-41.44M |
|
$-42.86M |
|
$-44.24M |
|
89.14M |
|
89.14M |
|
$-0.46 |
|
$-0.46 |
|
| Balance Sheet Financials | |
$186.89M |
|
$0.45M |
|
$7.71M |
|
$194.60M |
|
$21.42M |
|
-- |
|
$5.30M |
|
$26.72M |
|
|
Common Equity |
$167.88M |
$167.88M |
|
$167.88M |
|
89.16M |
|
| Cash Flow Statement Financials | |
$-65.07M |
|
$-20.66M |
|
$65.63M |
|
$78.84M |
|
$59.54M |
|
$-19.30M |
|
$14.18M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.72 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-65.10M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-24.69% |
|
-24.69% |
|
-21.30% |
|
-24.69% |
|
$1.88 |
|
$-0.73 |
|
$-0.73 |
|